Lupin and Zydus partner to combat liver disease and hepatitis

Friday, 3 November 2023
Lupin and Zydus Lifesciences announced they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden, and offers greater convenience for patients, the companies’ said. Lupin will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones.

👓 View full article

0 shares	Share Tweet Save Post Send

Lupin and Zydus partner to combat liver disease and hepatitis

You Might Like